7-Hydroxymitragynine

I need to be upfront with you about this one. I’ve covered hundreds of nootropics, adaptogens, and brain-supporting compounds on this site. Most of them, I’m genuinely excited about. 7-Hydroxymitragynine is different. This is a compound I feel obligated to cover — not because I think you should take it, but because concentrated 7-OH products are flooding gas stations and smoke shops across the country, and the gap between marketing hype and actual risk is dangerous.

Three people in Los Angeles died from 7-OH-related overdoses. Texas Poison Control saw an 80% spike in kratom/7-OH exposure reports in a single year. The FDA is actively pushing to make this a Schedule I substance.

If you’re here because you saw a flashy 7-OH product at a convenience store, this article might save you from a serious mistake. If you’re here because you use kratom and want to understand the science, I’ve got you covered there too.

The Short Version: 7-Hydroxymitragynine is a potent opioid-active alkaloid found naturally in trace amounts in kratom leaves. It’s roughly 13 times more potent than morphine and carries real risks of dependence, respiratory depression, and fatal overdose — especially in the concentrated, semi-synthetic products now widely available. There are zero controlled human clinical trials. This is not a nootropic in any meaningful sense — it’s an opioid alkaloid, and it deserves that level of respect and caution.

What Is 7-Hydroxymitragynine?

7-Hydroxymitragynine — usually called 7-OH — is a terpenoid indole alkaloid found naturally in the leaves of Mitragyna speciosa, better known as kratom. Kratom is a tropical tree in the coffee family native to Thailand, Malaysia, Indonesia, and surrounding regions, where it’s been used traditionally for centuries as a stimulant and pain reliever.

Here’s the critical detail most marketing materials leave out: in natural kratom leaf, 7-OH is a trace compound. It makes up less than 2% of total alkaloids and less than 0.05% of dried leaf weight. The dominant alkaloid in kratom is mitragynine, which accounts for roughly 66% of the alkaloid content. When you drink kratom tea or take whole-leaf kratom, you’re getting mostly mitragynine with only tiny amounts of 7-OH.

First isolated by researchers in 1994, 7-OH didn’t attract serious pharmacological attention until Matsumoto and colleagues demonstrated its potent oral analgesic activity in the early 2000s. Then in 2019, a pivotal study by Kruegel et al. in ACS Central Science revealed something that changed the picture entirely: your liver actually creates 7-OH from mitragynine. The enzyme CYP3A4 converts mitragynine into 7-OH, and brain concentrations of this metabolite are likely responsible for most of mitragynine’s painkilling effects.

So why the concern? Since roughly 2023, semi-synthetic and synthetic 7-OH products — pills, gummies, candies, shots — have flooded the US market with concentrations up to 98% pure 7-OH. That’s a completely different animal from chewing a kratom leaf. We’re talking about going from trace natural exposure to pharmaceutical-grade opioid concentrations sold next to energy drinks and vape pens.

How Does 7-Hydroxymitragynine Work?

Let’s cut through the complexity. At its core, 7-OH acts on the same brain receptors as morphine, codeine, and other opioids. It docks onto your mu-opioid receptors — the same ones responsible for pain relief, euphoria, and, yes, addiction and respiratory depression.

The technical picture is more nuanced. 7-OH binds to mu-opioid receptors (MOR) with a binding affinity of Ki = 37 nM — that’s roughly 9 times stronger than mitragynine’s grip on the same receptor. It also blocks delta-opioid and kappa-opioid receptors, which is pharmacologically interesting. Kappa receptor activation is associated with dysphoria (feeling terrible), so 7-OH’s kappa antagonism may partly explain why it produces more pleasurable effects than some other opioid compounds.

There is one genuinely interesting wrinkle in the pharmacology. Research by Kruegel & Grundmann (2017) in Neuropharmacology showed that both mitragynine and 7-OH are “G-protein biased” agonists at the mu-opioid receptor. In plain English: they activate the painkilling pathway preferentially over the pathway most responsible for respiratory depression and constipation in classical opioids. This is the same concept that major pharmaceutical companies have spent billions trying to engineer into synthetic opioids.

Reality Check: That G-protein bias sounds great on paper — and it genuinely is scientifically interesting. But “less respiratory depression than morphine” is not the same as “safe.” People have died from 7-OH products, particularly when combined with alcohol or other depressants. Biased signaling doesn’t make this risk-free. It makes it somewhat less dangerous than the most dangerous opioids — which is a very different claim than “safe.”

7-OH also shows activity at adrenergic, serotonergic, and dopaminergic receptors, which likely explains kratom’s unusual dose-dependent profile — stimulating at low doses, sedating at higher ones. But make no mistake: the dominant pharmacological action is opioid. This is an opioid compound.

One more critical detail: because CYP3A4 is the enzyme that converts mitragynine to 7-OH, anything that inhibits CYP3A4 — grapefruit juice, ketoconazole, erythromycin, ritonavir, and many other common medications — can significantly increase 7-OH levels in your body. This isn’t a minor footnote. It’s a drug interaction that could mean the difference between a manageable experience and a medical emergency.

Benefits of 7-Hydroxymitragynine

I’m going to be honest about the evidence here, because that’s what you deserve.

Pain relief is the most substantiated benefit, but entirely in animal models. 7-OH demonstrates roughly 40 times the analgesic potency of mitragynine and about 13 times the potency of morphine in standard pain-response tests in rodents. It’s also orally active — you don’t need to inject it — which is pharmacologically noteworthy. Some animal data suggests it may cause less respiratory depression than equivalent morphine doses, though this has not been confirmed in humans.

Opioid withdrawal support has some preclinical backing. A 2022 systematic review by Stanciu et al. found that rodent models support kratom alkaloids’ ability to reduce opioid withdrawal symptoms. User surveys echo this — many people report using kratom products to manage withdrawal from prescription opioids or heroin. However, these self-reports carry enormous selection and reporting bias, and substituting one opioid-active compound for another isn’t the same as treating addiction.

Mood effects are preliminary at best. A 2024 review by Green et al. in Progress in Neuro-Psychopharmacology and Biological Psychiatry noted that kratom constituents show potential in animal models of anxiety and depression. The multi-receptor profile (opioid + serotonergic + dopaminergic) theoretically supports mood modulation. But “animal models show potential” is the earliest possible stage of evidence — no human trials validate this.

Important: Let me be direct: there is no evidence that 7-OH is a nootropic. Zero evidence for cognitive enhancement. Zero evidence for neuroprotection. Zero evidence for memory, focus, or learning. If you’re looking for brain performance, this is the wrong compound. Look at Bacopa Monnieri, Lion’s Mane, or Citicoline instead.

How to Take 7-Hydroxymitragynine

I want to be responsible here, and responsible means telling you the truth: there is no established safe dosage for isolated 7-OH in humans. No clinical trials have mapped dose-response relationships. No medical body has published dosing guidelines.

What exists comes from product labels and user reports — neither of which constitutes medical guidance.

Commercial 7-OH products typically contain 5–22 mg per tablet. User-reported “low” doses range from 1–5 mg, with “moderate” doses around 5–10 mg. The problem is that the dose-response curve appears to be steep and narrow — meaning small increases in dose can produce disproportionately large increases in effect, including dangerous sedation and respiratory depression.

For context, if you’re consuming whole kratom leaf (2–5 grams), you’re getting only trace amounts of 7-OH directly. Your body also generates some 7-OH through liver metabolism of mitragynine, but the total exposure is dramatically lower than what concentrated products deliver.

Timing and duration based on user reports:

• Effects onset: 15–45 minutes for liquids, 1–2 hours for tablets/capsules
• Peak effects: 30–60 minutes after onset
• Total duration: 4–6 hours, with lingering effects up to 8 hours
• Food may slow absorption but reduce nausea

Pro Tip: If you currently use whole-leaf kratom and are considering your relationship with 7-OH: the natural alkaloid balance in whole kratom leaf — with its 40+ alkaloids at naturally occurring ratios — is a fundamentally different pharmacological experience than isolated 7-OH. Switching from whole leaf to concentrated 7-OH products is not “the same thing but stronger.” It’s a categorically different risk profile.

Tolerance develops rapidly with regular use, consistent with other opioid receptor agonists. No clinically validated cycling protocol exists. Users who develop tolerance commonly escalate doses — a pattern that dramatically increases risk.

The Side Effects Nobody Warns You About

The common side effects mirror what you’d expect from an opioid-active compound: nausea and vomiting, constipation, drowsiness, dry mouth, appetite suppression, and itching. These are the “manageable” end of the spectrum.

The serious end is what keeps me up at night.

Respiratory depression is the big one. At high doses or when combined with other depressants — especially alcohol — 7-OH can slow breathing to dangerous or fatal levels. The three fatal overdoses documented in Los Angeles County all involved alcohol co-use. This isn’t a theoretical risk. People are dying.

Physical dependence develops with regular use — sometimes within days to weeks. Withdrawal symptoms mirror opioid withdrawal: muscle aches, irritability, insomnia, diarrhea, anxiety, and restlessness. A 2025 review by Vadiei et al. in Current Psychiatry Reports emphasized that 7-OH demonstrates abuse liability in animal models and can substitute for morphine — unlike mitragynine, which doesn’t show the same abuse profile. This is a critical distinction that marketing materials conveniently omit.

Other serious risks include seizures (reported in both animal studies and human case reports), liver toxicity, and cardiac effects including tachycardia and arrhythmias.

Important: 7-OH should NEVER be combined with alcohol, other opioids, benzodiazepines (Xanax, Valium, Klonopin), sedatives, gabapentinoids, muscle relaxants, tramadol, or MAO inhibitors. These combinations can be fatal. Naloxone (Narcan) may not fully reverse 7-OH effects when other substances are involved.

Who should absolutely not take this:

• Anyone on opioid medications or with opioid use disorder history
• Anyone taking benzodiazepines or other CNS depressants
• People with liver disease (CYP3A4 metabolism is essential)
• People with respiratory conditions
• Anyone taking CYP3A4 or CYP2D6 inhibitors (many common medications fall into this category)
• Pregnant or nursing women — neonatal abstinence syndrome has been documented in infants born to kratom-using mothers, with more than half requiring pharmacological treatment

Stacking 7-Hydroxymitragynine

I’ll be blunt: this is not a substance that should be “stacked.”

The entire concept of nootropic stacking is built on combining compounds with complementary mechanisms to enhance cognitive function safely. 7-OH is an opioid-active alkaloid with a narrow therapeutic window, serious drug interactions, and no cognitive enhancement properties. Combining it with other substances for performance optimization is not a strategy — it’s a gamble.

The dangerous combinations are listed in the safety section above. To reiterate the most critical ones: alcohol, all opioids, all benzodiazepines, tramadol, sedatives, and CYP3A4 inhibitors. The combination of 7-OH with tramadol was involved in 9 deaths in Sweden (sold as “Krypton”).

If you’re looking for mood support, consider L-Theanine or Rhodiola Rosea. For pain management through non-opioid pathways, look into Palmitoylethanolamide or Boswellia. For stress resilience, Ashwagandha has actual human clinical trial data behind it.

My Take

I’ve been covering nootropics and cognitive enhancement since 2018. I’ve tried things that worked brilliantly, things that did nothing, and a few things I regret. I tell you this because I want you to understand where I’m coming from when I say: I cannot recommend 7-hydroxymitragynine products.

The science is genuinely interesting. G-protein biased opioid agonism is one of the most exciting concepts in pain pharmacology. The idea that kratom’s alkaloids might offer pain relief with less respiratory depression than classical opioids is worth pursuing — in proper clinical trials, with proper dosing, under proper medical supervision.

But that’s not what’s happening. What’s happening is that concentrated, semi-synthetic 7-OH is being sold in gas stations to teenagers who think it’s “just kratom.” According to Vadiei et al. (2025), these products “pharmacologically bear little similarity to traditional kratom” despite being marketed under the kratom name.

Here’s my honest breakdown:

If you use whole-leaf kratom responsibly — that’s a different conversation. Whole leaf contains trace 7-OH within a complex matrix of 40+ alkaloids at natural ratios. The risk profile, while not zero, is meaningfully different from isolated 7-OH.

If you’re looking at concentrated 7-OH products — tablets, shots, gummies marketed as “7-OH” or “7-Hydroxy” — please understand you are taking an opioid-potency compound with no established safe dose, no quality standards, documented fatalities, and a regulatory trajectory pointing straight at Schedule I.

If you’re struggling with pain — I genuinely empathize. Chronic pain is brutal, and the medical system often fails people. But the solution isn’t an unregulated opioid from a gas station. Talk to a practitioner about evidence-based options, including some of the compounds I’ve covered on this site that address pain through non-opioid mechanisms.

If you’re trying to manage opioid withdrawal — please seek professional help. Medication-assisted treatment with buprenorphine or methadone under medical supervision is vastly safer than self-medicating with concentrated 7-OH products.

The foundations-first principle I always come back to applies here more than anywhere: fix your sleep, address gut health, manage stress, optimize nutrition. These aren’t sexy answers. But they’re the ones that actually work without putting you at risk of dependence, overdose, or a substance that’s about to become a Schedule I controlled drug.